X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NATCO PHARMA ELDER PHARMA/
NATCO PHARMA
 
P/E (TTM) x -0.2 16.1 - View Chart
P/BV x 0.1 17.4 0.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NATCO PHARMA
Mar-14
ELDER PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs380877 43.3%   
Low Rs188424 44.4%   
Sales per share (Unadj.) Rs491.2223.4 219.8%  
Earnings per share (Unadj.) Rs-3.231.1 -10.2%  
Cash flow per share (Unadj.) Rs14.440.3 35.8%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5219.5 171.5%  
Shares outstanding (eoy) m20.5433.07 62.1%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x0.62.9 19.9%   
Avg P/E ratio x-89.320.9 -426.5%  
P/CF ratio (eoy) x19.716.1 122.1%  
Price / Book Value ratio x0.83.0 25.5%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m5,83321,504 27.1%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1791,128 193.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,0897,389 136.5%  
Other income Rs m257167 153.6%   
Total revenues Rs m10,3467,556 136.9%   
Gross profit Rs m-7921,793 -44.2%  
Depreciation Rs m361304 118.7%   
Interest Rs m2,756366 752.7%   
Profit before tax Rs m-3,6531,290 -283.2%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125309 40.5%   
Profit after tax Rs m-651,027 -6.4%  
Gross profit margin %-7.824.3 -32.3%  
Effective tax rate %-3.423.9 -14.3%   
Net profit margin %-0.613.9 -4.7%  
BALANCE SHEET DATA
Current assets Rs m9,2403,681 251.0%   
Current liabilities Rs m9,9983,123 320.2%   
Net working cap to sales %-7.57.6 -99.3%  
Current ratio x0.91.2 78.4%  
Inventory Days Days4689 51.8%  
Debtors Days Days6059 102.1%  
Net fixed assets Rs m10,1247,685 131.7%   
Share capital Rs m206331 62.2%   
"Free" reserves Rs m5,5826,670 83.7%   
Net worth Rs m7,7347,259 106.5%   
Long term debt Rs m4,889955 512.0%   
Total assets Rs m22,88211,957 191.4%  
Interest coverage x-0.34.5 -7.2%   
Debt to equity ratio x0.60.1 480.6%  
Sales to assets ratio x0.40.6 71.4%   
Return on assets %11.811.7 100.9%  
Return on equity %-0.814.2 -6.0%  
Return on capital %22.320.7 107.6%  
Exports to sales %3.039.4 7.7%   
Imports to sales %0.45.7 7.5%   
Exports (fob) Rs m3072,908 10.5%   
Imports (cif) Rs m43421 10.2%   
Fx inflow Rs m3073,445 8.9%   
Fx outflow Rs m125703 17.8%   
Net fx Rs m1812,743 6.6%   
CASH FLOW
From Operations Rs m11,7541,440 816.1%  
From Investments Rs m-561-1,089 51.5%  
From Financial Activity Rs m-6,762-353 1,917.2%  
Net Cashflow Rs m4,432-1 -297,429.5%  

Share Holding

Indian Promoters % 39.6 52.0 76.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 7.5 7.8 95.7%  
FIIs % 16.8 16.6 101.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 26.0 138.8%  
Shareholders   16,479 25,395 64.9%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PLETHICO PHARMA  BIOCON LTD  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS